Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
by David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 21 chart positions in 21 markets.
By chart position
- 🇺🇸US · Life Sciences#1105K to 30K
- 🇩🇪DE · Life Sciences#1175K to 30K
- 🇮🇹IT · Life Sciences#19100K to 300K
- 🇰🇷KR · Life Sciences#5410K to 30K
- 🇯🇵JP · Life Sciences#6310K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
76K to 248K🎙 Daily cadence·245 episodes·Last published today - Monthly Reach
Unique listeners across all episodes (30 days)
253K to 825K🇮🇹36%🇨🇿12%🇵🇹12%+18 more - Active Followers
Loyal subscribers who consistently listen
101K to 330K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 20 epsHost
Recent guests
Recent episodes
264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy - Part 2
Jun 25, 2026
15m 09s
263: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy - Part 1
Jun 23, 2026
16m 35s
262: How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics
Jun 18, 2026
15m 38s
261: Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts)
Jun 16, 2026
20m 23s
260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 2
Jun 11, 2026
21m 40s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/25/26 | 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy - Part 2 | Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success. For today’s episode, David Brühlmann is joined by David Hardy, a leader at Thermo Fisher Scientific. With years spent guiding automation and digital lab transformation projects around the globe, David’s perspective is equal parts pragmatic and visionary. He’s watched automati... | 15m 09s | ||||||
| 6/23/26 | 263: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy - Part 1 | Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurdle. David Hardy, a leading market and innovation strategist at Thermo Fisher Scientific with 25 years of experience at the intersection of data, automation, and laboratory science, is helping organizations bridge the gap between data chaos and actionable insight. Topics discus... | 16m 35s | ||||||
| 6/18/26 | 262: How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics | Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alternative expression platforms and offers a clear, practical framework for scientists navigating host cell decisions today. David Brühlmann moves past simplistic "replacement" narratives to instead examine where each technology, from plant farming to cell-free systems, fits in t... | 15m 38s | ||||||
| 6/16/26 | 261: Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts) | In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous data analysis, David examines where established and emerging hosts find their strengths—and their limits—in today’s biomanufacturing environment. Topics Discussed The historical dominance of CHO cells and what’s changed in the last decade (00:08)Three critical areas where alterna... | 20m 23s | ||||||
| 6/11/26 | 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 2✨ | fundingbiotech+3 | Michael Rome | Foresite Capital | — | fundingbiotech+5 | — | 21m 40s | |
| 6/9/26 | 259: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 1✨ | biotech fundinginvestor insights+3 | Michael Rome | Foresite Capital | — | biotechfunding+4 | — | 25m 12s | |
| 6/4/26 | 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 2✨ | regulatory affairsdrug design+4 | Milan Tomic | US government | — | regulatory affairsdrug design+5 | — | 24m 37s | |
| 6/2/26 | 257: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 1✨ | regulatory affairsdrug design+3 | Milan Tomic | Albrem | — | regulatory affairsdrug design+5 | — | 23m 34s | |
| 5/28/26 | 256: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 2✨ | bioprocess educationAI in manufacturing+3 | Steffen Kreye | BayerBerliner Hochschule für Technik | — | bioprocessingdata lake+5 | — | 18m 29s | |
| 5/26/26 | 255: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 1✨ | bioprocess educationAI in education+3 | Steffen Kreye | Berliner Hochschule für Technik | — | bioprocess educationAI+3 | — | 25m 42s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/21/26 | 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee - Part 2✨ | stem cellsallogeneic cell therapy+3 | Yuta Lee | Accelerated Bio | — | stem cellsallogeneic therapy+3 | — | 22m 27s | |
| 5/19/26 | 253: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee - Part 1✨ | stem cellscell therapy+3 | Yuta Lee | Accelerated Bio | — | stem cellsallogeneic cell therapy+3 | — | 23m 50s | |
| 5/14/26 | 252: How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds✨ | biosimilar developmentmedia supplements+3 | — | — | — | biosimilarglycan quality+3 | — | 18m 18s | |
| 5/12/26 | 251: Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works✨ | biosimilar developmentcompound screening+3 | — | — | — | DoEglycan optimization+3 | — | 18m 11s | |
| 5/7/26 | 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez - Part 2✨ | T Cell ActivationTIL Manufacturing+4 | Chantale Bernatchez | CTMC | — | T Cell ActivationTIL+4 | — | 20m 49s | |
| 5/5/26 | 249: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez - Part 1✨ | T Cell ActivationTIL Manufacturing+3 | Chantale Bernatchez | — | — | T Cell ActivationTIL+5 | — | 29m 11s | |
| 4/30/26 | 248: Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid with Ron Najafi - Part 2✨ | nitrosamine risk assessmentCRO selection+3 | Ron Najafi | NDMAranitidine+2 | — | nitrosamineCRO+7 | — | 19m 08s | |
| 4/28/26 | 247: Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid with Ron Najafi - Part 1✨ | drug safetynitrosamine contamination+4 | Ron Najafi | ranitidineNovaBay Pharmaceuticals+2 | — | nitrosaminedrug safety+5 | — | 32m 07s | |
| 4/23/26 | 246: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei - Part 2✨ | biomanufacturingbioprocessing+3 | Tibor Anderlei | Kühner Shaker | — | biomanufacturingshear sensitivity+3 | — | 22m 31s | |
| 4/21/26 | 245: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei - Part 1✨ | bioprocessingscale-up challenges+4 | Tibor Anderlei | Kühner ShakerAC Biotec | — | shake flaskscale-up+5 | — | 25m 41s | |
| 4/16/26 | 244: Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC✨ | tech transferbiologics+4 | — | — | — | tech transferbiologics+5 | — | 17m 45s | |
| 4/14/26 | 243: Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework✨ | tech transferbiologics+4 | — | — | — | biotechprocess development+3 | — | 14m 47s | |
| 4/9/26 | 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh - Part 2✨ | cell therapycryopreservation+3 | Steve Oh | XT Thrive®Arctic fish | — | DMSOcell therapy+5 | — | 17m 46s | |
| 4/7/26 | 241: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh - Part 1✨ | DMSOcell therapy+4 | Steve Oh | Singapore's A*STAR | Arctic | DMSOcell therapy+5 | — | 20m 26s | |
| 4/2/26 | 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer - Part 2 | Why do CDMOs keep building bigger stainless-steel facilities while their margins erode and Asian competitors undercut them on price? And what happens when big pharma decides to stop outsourcing altogether? The business model that sustained the industry for two decades is under pressure from every direction, and for many CDMOs, standing still is no longer a neutral position. In Part 2, Juergen Mairhofer, CEO of enGenes Biotech, shifts from the science to the stakes. Having spent over a decade ... | 18m 47s | ||||||
Showing 25 of 265
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
23 placements across 21 markets.
Chart Positions
23 placements across 21 markets.